Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic men

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 89, Issue 1, 2013, Pages 19-29

  Schuchardt, Jan Philipp ^a   Schmidt, Simone ^a   Kressel, Gaby ^a   Dong, Hua ^b   Willenberg, Ina ^c   Hammock, Bruce D ^b   Hahn, Andreas ^a   Schebb, Nils Helge ^c  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Arachidonic acid; Eicosanoids; Eicosapentaenoic acid; Hyperlipidemia; Omega 3 fatty acids; PUFA

Indexed keywords

DIHYDROXY FATTY ACID; EPOXY FATTY ACID; FATTY ACID DERIVATIVE; HYDROXY FATTY ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYLIPIN; POLYUNSATURATED FATTY ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE SEVERITY; ERYTHROCYTE MEMBRANE; FAT CONTENT; FATTY ACID ANALYSIS; FATTY ACID BLOOD LEVEL; FATTY ACID SYNTHESIS; HUMAN; HYPERLIPIDEMIA; LIPID DEGRADATION; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ADULT; ALPHA-LINOLENIC ACID; ARACHIDONIC ACID; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED;

EID: 84878977444     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2013.04.001     Document Type: Article

References (51)

1. Burdge G.C., Calder P.C. Conversion of α-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reprod. Nutr. Dev. 2005, 45:581-597.
2. Whelan J. The health implications of changing linoleic acid intakes. Prostag Leukotr Ess 2008, 79:165-167.
3. Brenna J.T., Salem N., Sinclair A.J., Cunnane S.C. α-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukotrienes Essent. Fatty Acids 2009, 80:85-91.
4. Plourde M., Cunnane S.C. Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl. Physiol. Nutr. Metabol.=Physiologie appliquee, nutrition et metabolisme 2007, 32:619-634.
5. Cabo J., Alonso R., Mata P. Omega-3 fatty acids and blood pressure. Br. J. Nutr. 2012, 107(Suppl. 2):S195-200.
6. Delgado-Lista J., Perez-Martinez P., Lopez-Miranda J., Perez-Jimenez F. Long chain omega-3 fatty acids and cardiovascular disease: a systematic review. Br. J. Nutr. 2012, 107(Suppl. 2):S201-213.
7. Ortega R.M., Rodriguez-Rodriguez E., Lopez-Sobaler A.M. Effects of omega 3 fatty acids supplementation in behavior and non-neurodegenerative neuropsychiatric disorders. Br. J. Nutr. 2012, 107(Suppl. 2):S261-270.
8. Rangel-Huerta O.D., Aguilera C.M., Mesa M.D., Gil A. Omega-3 long-chain polyunsaturated fatty acids supplementation on inflammatory biomarkers: a systematic review of randomised clinical trials. Br. J. Nutr. 2012, 107(Suppl. 2):S159-170.
9. Arnold C., Konkel A., Fischer R., Schunck W.H. Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol. Rep. 2010, 62:536-547.
10. Buczynski M.W., Dumlao D.S., Dennis E.A. Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J. Lipid Res. 2009, 50:1015-1038.
11. Psychogios N., Hau D.D., Peng J., Guo A.C., Mandal R., Bouatra S., Sinelnikov I., Krishnamurthy R., Eisner R., Gautam B., Young N., Xia J.G., Knox C., Dong E., Huang P., Hollander Z., Pedersen T.L., Smith S.R., Bamforth F., Greiner R., McManus B., Newman J.W., Goodfriend T., Wishart D.S. The human serum metabolome. Plos One 2011, 6. e16957, http://dx.doi.org/10.1371/journal.pone.0016957.
12. Shearer G.C., Harris W.S., Pedersen T.L., Newman J.W. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res. 2010, 51:2074-2081.
13. Brash A.R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 1999, 274:23679-23682.
14. Bylund J., Kunz T., Valmsen K., Oliw E.H. Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J. Pharmacol. Exp. Ther. 1998, 284:51-60.
15. Kroetz D.L., Zeldin D.C. Cytochrome P450 pathways of arachidonic acid metabolism. Curr. Opinion Lipidol. 2002, 13:273-283.
16. Morisseau C., Hammock B.D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 2005, 45:311-333.
17. Morisseau C., Inceoglu B., Schmelzer K., Tsai H.J., Jinks S.L., Hegedus C.M., Hammock B.D. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J. Lipid Res. 2010, 51:3481-3490.
18. Garscha U., Nilsson T., Oliw E.H. Enantiomeric separation and analysis of unsaturated hydroperoxy fatty acids by chiral column chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 872:90-98.
19. Niki E. Lipid peroxidation products as oxidative stress biomarkers. Biofactors 2008, 34:171-180.
20. Mulugeta S., Suzuki T., Hernandez N.T., Griesser M., Boeglin W.E., Schneider C. Identification and absolute configuration of dihydroxy-arachidonic acids formed by oxygenation of 5S-HETE by native and aspirin-acetylated COX-2. J. Lipid Res. 2010, 51:575-585.
21. Lee T.H., Austen K.F. Arachidonic acid metabolism by the 5-lipoxygenase pathway, and the effects of alternative dietary fatty acids. Adv. Immunol. 1986, 39:145-175.
22. Yeung J., Holinstat M. 12-lipoxygenase: a potential target for novel anti-platelet therapeutics. Cardiovasc. Hematol. Agents Med. Chem. 2011, 9:154-164.
23. Ford-Hutchinson A.W., Gresser M., Young R.N. 5-Lipoxygenase. Annu. Rev. Biochem. 1994, 63:383-417.
24. Vang K., Ziboh V.A. 15-lipoxygenase metabolites of gamma-linolenic acid/eicosapentaenoic acid suppress growth and arachidonic acid metabolism in human prostatic adenocarcinoma cells: possible implications of dietary fatty acids. Prostaglandins Leukotrienes Essent. Fatty Acids 2005, 72:363-372.
25. Yang J., Schmelzer K., Georgi K., Hammock B.D. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal. Chem. 2009, 81:8085-8093.
26. Spector A.A., Gordon J.A., Moore S.A. Hydroxyeicosatetraenoic acids (HETEs). Prog. Lipid Res. 1988, 27:271-323.
27. Stenson W.F., Parker C.W. Prostaglandins, macrophages, and immunity. J. Immunol. 1980, 125:1-5.
28. Heidel J.R., Taylor S.M., Laegreid W.W., Silflow R.M., Liggitt H.D., Leid R.W. In vivo chemotaxis of bovine neutrophils induced by 5-lipoxygenase metabolites of arachidonic and eicosapentaenoic acid. Am. J. Pathol. 1989, 134:671-676.
29. Kogure R., Toyama K., Hiyamuta S., Kojima I., Takeda S. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion. Biochem. Biophys. Res. Commun. 2011, 416:58-63.
30. Honn K.V., Tang D.G., Gao X., Butovich I.A., Liu B., Timar J., Hagmann W. 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev. 1994, 13:365-396.
31. Campbell W.B., Falck J.R. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension 2007, 49:590-596.
32. Fleming I. Vascular cytochrome P450 enzymes: physiology and pathophysiology. Trends Cardiovasc. Med. 2008, 18:20-25.
33. Thomson S.J., Askari A., Bishop-Bailey D. Anti-inflammatory effects of epoxyeicosatrienoic acids. Int. J. Vasc. Med. 2012, 2012:605101.
34. Fromel T., Jungblut B., Hu J., Trouvain C., Barbosa-Sicard E., Popp R., Liebner S., Dimmeler S., Hammock B.D., Fleming I. Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols. Proc. Natl. Acad. Sci. USA 2012, 109:9995-10000.
35. Gomolka B., Siegert E., Blossey K., Schunck W.H., Rothe M., Weylandt K.H. Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. Prostaglandins Lipid Mediators 2011, 94:81-87.
36. Strassburg K., Huijbrechts A.M., Kortekaas K.A., Lindeman J.H., Pedersen T.L., Dane A., Berger R., Brenkman A., Hankemeier T., van Duynhoven J., Kalkhoven E., Newman J.W., Vreeken R.J. Quantitative profiling of oxylipins through comprehensive LC-MS/MS analysis: application in cardiac surgery. Anal. Bioanal. Chem. 2012, 404:1413-1426.
37. Inceoglu B., Wagner K.M., Yang J., Bettaieb A., Schebb N.H., Hwang S.H., Morisseau C., Haj F.G., Hammock B.D. Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes. Proc. Natl. Acad. Sci. USA 2012, 109:11390-11395.
38. Shearer G.C., Newman J.W. Lipoprotein lipase releases esterified oxylipins from very low-density lipoproteins. Prostaglandins Leukotrienes Essent. Fatty Acids 2008, 79:215-222.
39. Poss J., Custodis F., Werner C., Weingartner O., Bohm M., Laufs U. Cardiovascular disease and dyslipidemia: beyond LDL. Curr. Pharm. Des. 2011, 17:861-870.
40. Gade W., Schmit J., Collins M., Gade J. Beyond obesity: the diagnosis and pathophysiology of metabolic syndrome. Clin. Lab. Sci. 2010, 23:51-61.
41. S. Grundy, D. Becker, L. Clark, R. Cooper, M. Denke, J. Howard, D. Hunninghake, R. Illingworth, R. Luepker, P. McBride, J. McKenney, R. Pasternak, N. Stone, L.V. Horn, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) National Cholesterol Education Program National Heart, Lung, and Blood NIH Publication no. 01-3670 2001, 2002.
42. Harris W.S., Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev. Med. 2004, 39:212-220.
43. Schebb N.H., Inceoglu B., Morisseau C., Ahn K.C., Gee S.J., Hammock B.D. Investigation of human exposure to triclocarban after showering, and preliminary evaluation of its biological effects. Environ. Sci. Technol. 2011, 45:3109-3115.
44. McLaughlin T., Abbasi F., Cheal K., Chu J., Lamendola C., Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med. 2003, 139:802-809.
45. Goodfriend T.L., Pedersen T.L., Grekin R.J., Hammock B.D., Ball D.L., Vollmer A. Heparin, lipoproteins, and oxygenated fatty acids in blood: a cautionary note. Prostaglandins Leukotrienes Essent. Fatty Acids 2007, 77:363-366.
46. Giordano R.M., Newman J.W., Pedersen T.L., Ramos M.I., Stebbins C.L. Effects of dynamic exercise on plasma arachidonic Acid epoxides and diols in human volunteers. Int. J. Sport Nutr. Exercise Metab. 2011, 21:471-479.
47. Arnold C., Markovic M., Blossey K., Wallukat G., Fischer R., Dechend R., Konkel A., von Schacky C., Luft F.C., Muller D.N., Rothe M., Schunck W.H. Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of {omega}-3 fatty acids. J. Biol. Chem. 2010, 285:32720-32733.
48. Neubronner J., Schuchardt J.P., Kressel G., Merkel M., von-Schacky C., Hahn A. Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters. Eur. J. Clin. Nutr. 2012, 65:247-254.
49. Zhang M.J., Spite M. Resolvins: anti-inflammatory and proresolving mediators derived from omega-3 polyunsaturated fatty acids. Ann. Rev. Nutr. 2012, 32:203-227.
50. Keenan A.H., Pedersen T.L., Fillaus K., Larson M.K., Shearer G.C., Newman J.W. Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J. Lipid Res. 2012, 53:1662-1669.
51. Inceoglu B., Wagner K., Schebb N.H., Morisseau C., Jinks S.L., Ulu A., Hegedus C., Rose T., Brosnan R., Hammock B.D. Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proc. Natl. Acad. Sci. USA 2011, 108:5093-5097.